Back

Stanley I R Okoduwa

Stanley I R Okoduwa

Stanley I R Okoduwa, Nigerian Institute of Leather and Science Technology, Nigeria

Title: Appropriate insulin level in selecting fortified diet-fed, streptozotocin-treated rat model of type 2 diabetes for anti-diabetic studies

Biography

Stanley I. R. Okoduwa is a doctoral scholar from Ahmadu Bello University, Zaria Nigeria and a Research officer at the Nigerian Institute of Leather and Science Technology, Zaria Nigeria. He is the co-founder of Info-health Awareness Group, a non for profit organization under the SIRONigeria Global Limited, Abuja-Nigeria, whose mission is geared towards eradication of preventable diseases in Nigeria. His passion is on innovative research that would improve the quality of human life. He has published and co-authored several articles in reputable journals and has been serving as a peer reviewer to high profile journals.  

Abstract

Pathophysiological investigation of disease in a suitable animal model is a classical approach towards development of credible therapeutic strategy. This study examined appropriate insulin level in selecting animal model for type 2 diabetes (T2D) studies. Albino wistar rats (150-200g) were divided into two groups fed with commercially available normal-diet-feed (NDF) and water or fortified diet feed (FDF) (10g NDF per gram of margarine) with 20% fructose-solution as drinking-water. After 6 weeks of dietary regimen both groups were divided into 5 sub-groups and injected intraperitoneally with graded dose of streptozotocin (STZ) (0, 25, 35, 45 & 55-mg/kg b.w.). The result showed that the FDF-fed rats increased significantly in body weight, basal serum insulin, total cholesterol, triglycerides and blood glucose levels as compared to NDF-fed rats. Ten days post STZ induction, the groups treated with STZ (45 & 55 mg/kg) developed frank hyperglycemia with < 46.8% serum-insulin, a severe deficiency typical of diabetes type-1. The NDF25 and NDF35 groups with 75.7 and 64.4% serum insulin respectively presented relatively normoglycemia, whereas the FDF35 (85.8% serum insulin) were notably hyperglycemia ( >300 mg/dL) throughout the 6-weeks post diabetes confirmation. This FDF35 rats were sensitive to glibenclamide, metformin and pioglitazone in lowering hyperglycemia, hypertriglyceridemia and hypercholesterolemia, thus proved to be a suitable non-genetic stable model for T2D studies. The study suggests that circulating serum-insulin > 85.8% with overt hyperglycemia may be utilized as the benchmark in selecting animal-model for T2D studies.